Loading...

Brian Jonas

Title(s)Assistant Professor, Hematology and Oncology
SchoolUniversity of California, Davis
Phone916-734-3772
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019 Oct 18. PMID: 31628431.
      View in: PubMed
    2. Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 Nov; 94(11):E291-E294. PMID: 31379016.
      View in: PubMed
    3. Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 Jul; 20(7):984-997. PMID: 31175001.
      View in: PubMed
    4. Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS. Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 Aug; 19(8):509-515.e1. PMID: 31227358.
      View in: PubMed
    5. Malfatti MA, Buchholz BA, Enright HA, Stewart BJ, Ognibene TJ, McCartt AD, Loots GG, Zimmermann M, Scharadin TM, Cimino GD, Jonas BA, Pan CX, Bench G, Henderson PT, Turteltaub KW. Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science. Toxics. 2019 May 09; 7(2). PMID: 31075884.
      View in: PubMed
    6. Lin TY, Zhu Y, Li Y, Zhang H, Ma AH, Long Q, Keck J, Lam KS, Pan CX, Jonas BA. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine. 2019 Aug; 20:102004. PMID: 31055076.
      View in: PubMed
    7. Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol. 2019 Jul; 94(7):803-811. PMID: 30945331.
      View in: PubMed
    8. Galkin M, Jonas BA. Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. Core Evid. 2019; 14:3-17. PMID: 31118877.
      View in: PubMed
    9. Rosenberg AS, Brunson A, Jonas BA, Keegan THM, Wun T. Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. J Natl Cancer Inst. 2019 Jan 01; 111(1):78-85. PMID: 29897481.
      View in: PubMed
    10. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 01 03; 133(1):7-17. PMID: 30361262.
      View in: PubMed
    11. Ho G, Li Q, Brunson A, Jonas BA, Wun T, Keegan THM. Complications and early mortality in patients with acute promyelocytic leukemia treated in California. Am J Hematol. 2018 11; 93(11):E370-E372. PMID: 30105792.
      View in: PubMed
    12. Scharadin TM, Malfatti MA, Haack K, Turteltaub KW, Pan CX, Henderson PT, Jonas BA. Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing. Chem Res Toxicol. 2018 10 15; 31(10):1042-1051. PMID: 30152692.
      View in: PubMed
    13. Davis JR, Benjamin DJ, Jonas BA. New and emerging therapies for acute myeloid leukaemia. J Investig Med. 2018 12; 66(8):1088-1095. PMID: 30127098.
      View in: PubMed
    14. Wung W, Ananthakrishnan S, Jonas BA. Proteinuria, Hypoalbuminemia, and Chronic Lymphocytic Leukemia: An Unusual Trio. J Investig Med High Impact Case Rep. 2018 Jan-Dec; 6:2324709618764207. PMID: 29568782.
      View in: PubMed
    15. Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, Jonas BA, Keegan THM. Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. Cancer. 2018 05 01; 124(9):1938-1945. PMID: 29451695.
      View in: PubMed
    16. DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 02; 19(2):216-228. PMID: 29339097.
      View in: PubMed
    17. Kjelland JD, Dwyre DM, Jonas BA. Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia. Case Rep Hematol. 2017; 2017:3625946. PMID: 29158926.
      View in: PubMed
    18. Rosenberg AS, Brunson A, Paulus JK, Tuscano J, Wun T, Keegan THM, Jonas BA. Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. Blood Cancer J. 2017 09 08; 7(9):e605. PMID: 28885611.
      View in: PubMed
    19. Jonas BA. On the origin of relapse in AML. Sci Transl Med. 2017 07 12; 9(398). PMID: 28701479.
      View in: PubMed
    20. Jonas BA. A new therapeutic target for myelofibrosis is cause for Gli. Sci Transl Med. 2017 05 31; 9(392). PMID: 28566426.
      View in: PubMed
    21. Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, Keegan THM. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Br J Haematol. 2017 07; 178(1):72-80. PMID: 28542862.
      View in: PubMed
    22. Jonas BA. Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check. Sci Transl Med. 2017 04 19; 9(386). PMID: 28424330.
      View in: PubMed
    23. Ho G, Jonas BA, Li Q, Brunson A, Wun T, Keegan THM. Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. Br J Haematol. 2017 06; 177(5):791-799. PMID: 28419422.
      View in: PubMed
    24. Jonas BA. From MDS/AML to iPSC and back again. Sci Transl Med. 2017 03 08; 9(380). PMID: 28275157.
      View in: PubMed
    25. Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res. 2016 11; 50:123-131. PMID: 27736729.
      View in: PubMed
    26. Su RJ, Jonas BA, Welborn J, Gregg JP, Chen M. Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia. Hum Pathol (N Y). 2016 Sep; 5:6-9. PMID: 27458550.
      View in: PubMed
    27. Jonas BA, Johnson C, Gratzinger D, Majeti R. Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity. PLoS One. 2016; 11(7):e0159189. PMID: 27428079.
      View in: PubMed
    28. Jonas BA, Medeiros BC. Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach. Oncology (Williston Park). 2016 Apr; 30(4):330, 333. PMID: 27085331.
      View in: PubMed
    29. Ali SF, Sonu RJ, Dwyre DM, Jonas BA, Rashidi HH. Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome. Case Rep Hematol. 2015; 2015:318545. PMID: 26798525.
      View in: PubMed
    30. Stelling A, Jonas BA, Rashidi HH, Abedi M, Chen M. Acute Myeloid Leukemia with Isolated Trisomy 19 Associated with Diffuse Myelofibrosis and Osteosclerosis. Cancers (Basel). 2015 Dec 14; 7(4):2459-65. PMID: 26694466.
      View in: PubMed
    31. Song JY, Khojeini EV, Dwyre DM, Jonas BA. B lymphoblastic leukemia with granules mimicking acute myeloid leukemia. Int J Hematol. 2015 Sep; 102(3):251-2. PMID: 26187696.
      View in: PubMed
    32. Sonu RJ, Jonas BA, Dwyre DM, Gregg JP, Rashidi HH. Optimal Molecular Methods in Detecting p190 (BCR-ABL) Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature. Case Rep Hematol. 2015; 2015:458052. PMID: 25949834.
      View in: PubMed
    33. McCoach CE, Rogers JG, Dwyre DM, Jonas BA. Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer. Cancer Treat Commun. 2015; 4:15-18. PMID: 25932381.
      View in: PubMed
    34. Jonas BA, Greenberg PL. MDS prognostic scoring systems – past, present, and future. Best Pract Res Clin Haematol. 2015 Mar; 28(1):3-13. PMID: 25659725.
      View in: PubMed
    35. Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX. Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. Nanomedicine (Lond). 2014; 9(12):1807-20. PMID: 24628688.
      View in: PubMed
    36. Goodson ML, Mengeling BJ, Jonas BA, Privalsky ML. Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation. J Biol Chem. 2011 Dec 30; 286(52):44988-99. PMID: 22065574.
      View in: PubMed
    37. Jonas BA, Varlakhanova N, Hayakawa F, Goodson M, Privalsky ML. Response of SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) and N-CoR (nuclear receptor corepressor) corepressors to mitogen-activated protein kinase kinase kinase cascades is determined by alternative mRNA splicing. Mol Endocrinol. 2007 Aug; 21(8):1924-39. PMID: 17519355.
      View in: PubMed
    38. Goodson M, Jonas BA, Privalsky MA. Corepressors: custom tailoring and alterations while you wait. Nucl Recept Signal. 2005; 3:e003. PMID: 16604171.
      View in: PubMed
    39. Goodson ML, Jonas BA, Privalsky ML. Alternative mRNA splicing of SMRT creates functional diversity by generating corepressor isoforms with different affinities for different nuclear receptors. J Biol Chem. 2005 Mar 04; 280(9):7493-503. PMID: 15632172.
      View in: PubMed
    40. Jonas BA, Privalsky ML. SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways. J Biol Chem. 2004 Dec 24; 279(52):54676-86. PMID: 15491994.
      View in: PubMed